Uniqure NV Aktie - UQ1

Professionelle Tools für Privatanleger.

Premium

Current Price

12,235

Gebot

12,115

Fragen

12,42

Volumen

0,00

0,00 Tagesbereich 0,00

3,548 52-Wochen-Bereich 18,38

Handelsende

12,235

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

766

Finanzvolumen

VWAP

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer ~ Proven biotech executive to lead commercialization of...

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease ~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~...

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) ~ No serious adverse...

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress ~ AMT-130 granted Breakthrough Therapy...

uniQure to Announce First Quarter 2025 Financial Results

uniQure to Announce First Quarter 2025 Financial Results ~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET...

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease ~ Breakthrough Therapy...

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress ~ Announced alignment with the U.S. Food and Drug Administration...

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its...

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the...

uniQure Announces Pricing of its Public Offering

uniQure Announces Pricing of its Public Offering LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.8	-6.13732259302	13.035	13.035	12	1054	12.61956365	DE
4	-1.62	-11.6925297726	13.855	15.68	12	830	13.34040657	DE
12	3.8010001	45.0675853103	8.4339999	15.68	7.21	766	11.98817388	DE
26	-4.455	-26.6926303176	16.69	18.38	7.21	597	12.51765308	DE
52	8.001	188.970240907	4.234	18.38	3.548	1164	10.40257067	DE
156	-6.02	-32.9772665023	18.255	25.61	3.548	1004	9.08028214	DE
260	-19.225	-61.1093452003	31.46	32.78	3.548	584	10.1244645	DE

UQ1 - Frequently Asked Questions (FAQ)

What is the current Uniqure NV share price?

The current share price of Uniqure NV is 12,235 €

What is the 1 year trading range for Uniqure NV share price?

Uniqure NV has traded in the range of 3,548 € to 18,38 € during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
SS6Pan American Energy Corp	0,25 € (28,21%)	13k
FLBStandard BioTools Inc	1,30 € (22,64%)	3,5k
DRHDroneShield Limited	1,152 € (20,13%)	2,39M
2N6Labrador Gold Corp	0,0614 € (18,08%)	144
0IUUS Critical Metals Corp	0,1799 € (13,86%)	78,3k
E3O1Nexoptic Technology Corp	0,0055 € (-31,25%)	2,67k
WS90Provaris Energy Ltd	0,0066 € (-26,67%)	16k
N7ENatural Cool Holdings Limited	0,02 € (-23,08%)	6k
BR01Cruz Battery Metals Corp	0,0085 € (-22,73%)	10k
PU11Social Chain AG	0,0125 € (-21,88%)	50
DRHDroneShield Limited	1,152 € (20,13%)	2,39M
DN3Metaplanet Inc	9,48 € (-0,63%)	581,97k
TUI1Tui AG	7,126 € (1,51%)	345,83k
FMGFirst Mining Gold Corp	0,113 € (-7,38%)	334,36k
8J30Ebusco Holding NV	0,5005 € (-10,38%)	317,56k

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Uniqure NV (UQ1)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

UQ1 Neueste Nachrichten

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

uniQure to Announce First Quarter 2025 Financial Results

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

uniQure Announces Pricing of its Public Offering

UQ1 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Uniqure NV (UQ1) Börsenkurse

Uniqure NV (UQ1)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

UQ1 Neueste Nachrichten

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

uniQure to Announce First Quarter 2025 Financial Results

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

uniQure Announces Pricing of its Public Offering

UQ1 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Anmelden

Werbung entfernen